{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:35:53Z","timestamp":1756384553392,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:00:00Z","timestamp":1522972800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670560"],"award-info":[{"award-number":["81670560"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12876-018-0773-3","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T10:34:54Z","timestamp":1524134094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B"],"prefix":"10.1186","volume":"18","author":[{"given":"Yue","family":"Ying","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Lin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Xian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,6]]},"reference":[{"key":"773_CR1","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1002\/hep.22885","volume":"49","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49:S185\u201395.","journal-title":"Hepatology"},{"issue":"2","key":"773_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV, GLOBE Study Group. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136(2):486\u201395.","journal-title":"Gastroenterology"},{"issue":"2","key":"773_CR3","first-page":"57","volume":"1","author":"B Caroleo","year":"2011","unstructured":"Caroleo B, Galasso O, Staltari O, Girofr\u00e8 C, De Sarro G, Guadagnino V, Gallelli L. Muscular damage during telbivudine treatment in a chronic hepatitis B patient. Muscles, Ligaments and Tendons Journal. 2011;1(2):57\u201360.","journal-title":"Muscles, Ligaments and Tendons Journal"},{"key":"773_CR4","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","volume":"19","author":"HL Chan","year":"2012","unstructured":"Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-na\u00efve patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012;19:732\u201343.","journal-title":"J Viral Hepat"},{"issue":"12","key":"773_CR5","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/j.1365-2893.2010.01412.x","volume":"18","author":"XJ Zou","year":"2011","unstructured":"Zou XJ, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J Viral Hepat. 2011;18(12):892\u20136.","journal-title":"J Viral Hepat"},{"issue":"9","key":"773_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162760","volume":"11","author":"T Ambang","year":"2016","unstructured":"Ambang T, Tan JS, Ong S, Wong KT, Goh KJ. Clinicopathological Features of Telbivudine-Associated Myopathy. PLoS One. 2016;11(9):e0162760.","journal-title":"PLoS One"},{"issue":"1","key":"773_CR7","first-page":"66","volume":"25","author":"ZM Yi","year":"2016","unstructured":"Yi ZM, Tang SD, Fang L, Zhai SD, Jiao LG. Evaluation on telbivudine-associated rhabdomyolysis. J Clin Pharm Sci. 2016;25(1):66\u201372.","journal-title":"J Clin Pharm Sci"},{"key":"773_CR8","doi-asserted-by":"crossref","unstructured":"Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, Zoulim F, Tacke F. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"773_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13256-015-0671-z","volume":"9","author":"V Suttels","year":"2015","unstructured":"Suttels V, Florence E, Leys J, Vekemans M, Van den Ende J, Vlieghe E, Kenyon C. A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate and pravastatin\/fenofibrate: a case report. J Med Case Rep. 2015;9:190.","journal-title":"J Med Case Rep"},{"issue":"3","key":"773_CR10","first-page":"262","volume":"47","author":"S Callens","year":"2003","unstructured":"Callens S, De Roo A, Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Inf Secur. 2003;47(3):262\u20133.","journal-title":"J Inf Secur"},{"issue":"6","key":"773_CR11","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.jhep.2014.07.019","volume":"61","author":"P Marcellin","year":"2014","unstructured":"Marcellin P, Buti M, Krastev Z, de Man RA, Zeuzem S, Lou L, Gaggar A, Flaherty JF, Massetto B, Lin L, Dinh P, Subramanian GM, McHutchison JG, Flisiak R, Gurel S, Dusheiko GM, Heathcote EJ. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol. 2014;61(6):1228\u201337.","journal-title":"J Hepatol"},{"issue":"2","key":"773_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054279","volume":"8","author":"T Piratvisuth","year":"2013","unstructured":"Piratvisuth T, Komolmit P, Tanwandee T, Sukeepaisarnjaroen W, Chan HL, Pessoa MG, Fassio E, Ono SK, Bessone F, Daruich J, Zeuzem S, Cheinquer H, Pathan R, Dong Y, Trylesinski A. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One. 2013;8(2):e54279.","journal-title":"PLoS One"},{"issue":"2","key":"773_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40121-014-0039-5","volume":"3","author":"NW Leung","year":"2014","unstructured":"Leung NW, Herrmann E, Lau GK, Chan HL, So TM, Zeuzem S, Dong Y, Trylesinski A, Naoumov NV. Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. Infect Dis Ther. 2014;3(2):191\u2013202.","journal-title":"Infect Dis Ther"},{"key":"773_CR14","doi-asserted-by":"publisher","first-page":"40847","DOI":"10.1074\/jbc.M106743200","volume":"276","author":"AA Johnson","year":"2001","unstructured":"Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, Johnson KA. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem. 2001;276:40847\u201357.","journal-title":"J Biol Chem"},{"issue":"3-4","key":"773_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/em.20223","volume":"48","author":"JJ Kohler","year":"2007","unstructured":"Kohler JJ, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen. 2007;48(3-4):166\u201372.","journal-title":"Environ Mol Mutagen"},{"key":"773_CR16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1128\/AAC.01122-07","volume":"52","author":"CE Mazzucco","year":"2008","unstructured":"Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother. 2008;52:598\u2013605.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-018-0773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-018-0773-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-018-0773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T19:07:47Z","timestamp":1554491267000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-018-0773-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,6]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1186\/s12876-018-0773-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"type":"electronic","value":"1471-230X"}],"subject":[],"published":{"date-parts":[[2018,4,6]]},"assertion":[{"value":"16 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent to participate in the study from the patient was obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication from the patient was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"45"}}